1. Scrip
  2. >>Business

Pfizer, Lilly Seek To Halt ‘Infringing’ Drugs From Across Border In India

 
• By Anju Ghangurde

"Illegal" copies of Pfizer’s Lorbriqua and Eli Lilly’s Verzenio have been seen making their way to India allegedly via manufacturers in Bangladesh. The US multinationals are engaged in a legal battle in India to tackle the ‘infringement’ amid wider concerns around inadequate regulatory oversight.

Pfizer, Lilly seek to ward off infringers for key drugs • Source: Shutterstock

US multinationals Pfizer Inc. and Eli Lilly and Company are engaged in a multi-pronged legal battle in India, with charges that spill into alleged actions emanating from bordering nation Bangladesh.

Both companies have claimed that infringing generic copies of certain patented anti-cancer drugs – Pfizer’s lorlatinib (sold as Lorbriqua) and Lilly’s abemaciclib

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.